Qureight, an end-to-end imaging startup serving clinical trials, has raised £15 million in a Series B financing led by Molten Ventures, with participation from Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension. Working with biopharma partners, Qureight provides enterprise-grade imaging and precision endpoints for trials in lung and heart disease. Inga Deakin of Molten Ventures and Anna Salim of Hargreave Hale join the Board of Directors.
The platform brings together global imaging CRO services, which improve image handling in clinical trials and support rapid site onboarding and patient inclusion decisions, and proprietary AI lung image biomarkers that quantify compartment specific structural changes indicating disease progression. Data science products including synthetic control arms enable comparisons to real trial arms, reducing study costs and duration. Biopharma partners already use these services for real-time insights and precision endpoints across a number of fibrotic lung diseases.
New capital will fund an AI imaging laboratory to house Qureight's 3D chest imaging Foundation Model, significantly reducing both the data requirement and the time needed to develop new disease models. That work is intended to open up asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity, complementing existing models in lung fibrosis, alongside further development of the quantitative imaging analytics platform and expansion of the commercial team. The global lung and heart clinical trials market is expected to grow to USD $27.5bn by 2030, with a CAGR of 6.9% over the next six years.
The global lung and heart clinical trials market is expected to grow to USD $27.5bn by 2030, with a CAGR of 6.9% over the next six years. We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials. We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors. I also welcome Anna Salim of Hargreave Hale to the Board, and thank all of our existing investors who participated in this round. Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world class team, to address a critical demand to accelerate clinical trials. Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market.
Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team's rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision.
